This review assessed the effects of gemcitabine for cholangiocarcinoma and gallbladder cancer. The authors concluded that where surgery is inappropriate, gemcitabine alone or combined with a fluoropyrimidine appears a reasonable option. There was limited evidence from small observational studies that recruited patients with unknown characteristics; a more cautious conclusion may have been more appropriate.
Data extraction
The authors did not state how the data were extracted for the review, or how many reviewers performed the data extraction. For each study, the number of patients used in the evaluation of response and toxicity, the response rate, median survival, 1-year survival, and the number with specified adverse effects were extracted, where possible.
Methods of synthesis
How were the studies combined?
The studies were grouped according to the interventions (monotherapy or combination therapy) and combined in a narrative.
How were differences between studies investigated?
Differences between the studies were apparent from the description of individual studies and from inspection of the tables.
Results of the review
Thirteen single-arm phase II studies (n=420) were included.
Gemcitabine monotherapy (3 studies, n=79; sample size: 23 to 30).
The response rates ranged from 30% (2 studies) to 36% (1 study). None of the patients experienced a complete response. Median survival ranged from 30 to 56 weeks, while 1-year survival ranged from 16 to 57%.
One study reported no gastrointestinal toxicity or grade 3 or 4 haematological toxicity, while another reported no grade 4 toxicity. The most commonly reported grade 3 to 4 adverse effects were nausea (13%), neutropenia (3.3% and either 13% or 4% in a second study, it was not clear which), anaemia (4%), flu-like symptoms (4%), haemolytic uraemic syndrome (4%) and anorexia (3.3%).
Gemcitabine plus cisplatin (3 studies, n=85; sample size: 11 to 44).
The response rates ranged from 36.6 to 50%. Complete response rates ranged from 9 to 27%. Median survival ranged from 20 to 45.2 weeks, while 1-year survival was 18.6% in the only study reporting this outcome.
A total of four patients died during treatment (cerebral ischaemia, unknown cause, renal toxicity and disease progression). The most common adverse effects were grade 3 and 4 thrombocytopenia (18%, 16.6% and 2%), anaemia (36.6% and 14%), neutropenia (0%, 23% and 33.2%), fever (9%), asthenia (9%) and granulocytopenia (9%).
Gemcitabine plus 5-FU/leucovorin (2 studies, n=72; sample size: 30 and 42).
The response rates were 9.5% and 21.4%. None of the patients achieved a complete response. Median survival was 38.8 and 18.8 weeks, while 1-year survival rates were 14% and 20%.
The most common adverse effects were grade 3 and 4 infection (31%), nausea and vomiting (19% and 7%), fatigue (17%), leukopenia (14%) and thrombocytopenia (14% and 10%).
Gemcitabine plus capecitabine (1 study, n=45).
The response rate was 31% and 4% achieved a complete response. Median survival was 56 weeks and 1-year survival was 49%.
The most common grade 3 and 4 adverse effects were neutropenia (34%), thrombocytopenia (11%), hand-foot rash (9%), and infection and fatigue (both 4%).
